

## **REMARKS**

### ***Claims Status***

Claims 1-43 are pending and are subject to restriction in the Office Action mailed March 15, 2010.

### ***Response to Restriction Requirement***

The Office Action requires restriction under 35 USC § 121 among six designated groups of claimed subject matter. In response, Applicants hereby elect Group I defined as a pseudo-sequence method of comparing 7TM receptors, namely, Claims 2-6 and 14-38.

The Office Action requires election of a single species of a "receptor." In response, Applicants hereby elect a Class A receptor, the name and structure of which are recited in Claim 19 as originally filed. The claims of Group I readable thereon are believed to be at least Claims 2-6 and 14-38.

Furthermore, the Office Action requires election of a single species of a "method of calculating a similarity score." In response, Applicants hereby elect a method of calculating a similarity score as recited in Claim 35 (Tanimoto Similarity Measure:  $TC=BC/(B1+B2-BC)$ ), the name and formula of which is disclosed in the specification as originally filed at page 27, lines 29 and 30. The claims of Group I readable thereon are believed to be at least Claims 1, 17, 28 and 35.

Applicants note that Groups I-VI encompass restriction between inventions linked by Claim 1. Applicants respectfully request full rejoinder upon allowance of linking Claim 1.

### ***Informalities***

Applicants hereby concurrently submit the following formal documents:

- 1) Power of Attorney to Prosecute Applications Before the USPTO.
- 2) Statement Under 37 CFR 3.73(b).

**Conclusion**

The Examiner is welcome to call or otherwise contact the undersigned for any reason pertaining this application.

Respectfully submitted,

/Jeffrey McQuiston/  
Jeffrey M. McQuiston  
Agent for Applicants  
Reg. No. 63,109  
Tel: (631) 962-2034  
Fax: (631) 845-0582

Date: April 15, 2010  
OSI Pharmaceuticals, Inc.  
41 Pinelawn Road  
Melville, NY 11747 USA